PureTech Founded Entity Seaport Therapeutics Announces Publication of New Research Demonstrating Increased Lymphatic Transport with Glyph Platform ...

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at where United Therapeutics Corporation (NASDAQ:UTHR) stands against the ...

Michael Benkowitz, President and COO of United Therapeutics Corp (NASDAQ:UTHR), a $15.77 billion market cap company with an "Excellent" financial health rating according to InvestingPro, executed a ...

FDA clears United Therapeutics for human trials of pig-to-human kidney transplants. Trial involves gene-edited pig kidneys ...

Michael Benkowitz, President and COO of United Therapeutics Corp (NASDAQ:UTHR), recently executed a series of stock transactions, according to a recent SEC filing. On February 3, Benkowitz sold shares ...

This is a recurring post, regularly updated with new information and offers. Although 2024 has ended, there may still be an opportunity to snag the next level of United Premier status for 2025. United ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

However, Wall Street's enthusiasm for Summit Therapeutics appears to be justified. If ivonescimab fulfills its potential, Summit should be worth a lot more within a few years than it is today.

Thanks for joining us at Al Jazeera Sport. Brighton beat Manchester United in Matchweek 22 of the English Premier League season. Goals from Yankuba Minteh, Karou Mitoma and Giorginio Rutter sealed ...

View United Therapeutics Corporation (UTHR) current and estimated P/E ratio data provided by Seeking Alpha.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

These companies valuations have fluctuated since - Exelixis' is now valued at $10.65bn, Genmab, $13.7bn, Alnylam, $32.4bn, BioMarin, $11.7bn, and United Therapeutics, $16.1bn, while Sarepta's ...